Latest market price per box of Trientine capsules

Trientine (Trientine) is a core drug used to treat the rare disease Wilson's disease, and its market price has been at a high level for a long time. This is mainly due to the nature of its original drug, high production costs and restrictions on supply channels. At present, trientine has not yet been fully marketed in China and can only be obtained through specific imported drug channels or overseas medical purchasing platforms. Therefore, access channels and prices have become issues of greater concern to domestic patients.

The main specifications of original research trientine capsules that are more common on the market are 200mg*100 capsules, with the trade name Syprine, and are sold in Europe, the United States, Germany, France and other countries. According to international drug import quotations and exchange rate fluctuations, the price of drugs of this specification is usually more than 40,000 yuan. The specific price needs to be combined with the drug purchase channels and local tax policies. Some domestic import platforms introduce the drug through formal channels, and the price will also be adjusted due to drug batches, warehousing, transportation and market fluctuations.

In overseas markets, some pharmaceutical companies in India have also begun to launch generic versions of trientine. Although its ingredients are highly consistent with the original drug, its legality and quality safety still need to be clarified by supervision in some countries because it has not yet received widespread drug registration approval in mainstream European and American markets. The price of Indian generic drugs is generally lower than that of original drugs, making them an alternative choice for some patients with limited economic conditions. However, you should consult a professional doctor or pharmaceutical expert before use to ensure that they meet the treatment needs of individual conditions.

Overall, the high price of trientine in the Chinese market is mainly limited by the import nature of the original drug, market monopoly, and restrictions on rare disease drug policies. In the future, if domestic pharmaceutical companies successfully imitate or more original manufacturers enter the Chinese market, the price of trientine may decline considerably.

Reference materials:https://www.cufence.com/